Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.26M P/E - EPS this Y - Ern Qtrly Grth -
Income -7.94M Forward P/E 0.00 EPS next Y - 50D Avg Chg -7.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -42.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -87.00%
Recommedations - Quick Ratio 0.00 Shares Outstanding 630.41M 52W Low Chg 60.00%
Insider Own - ROA - Shares Float - Beta 1.19
Inst Own - ROE - Shares Shorted/Prior -/- Price 0.00080
Gross Margin - Profit Margin - Avg. Volume 972,966 Target Price -
Oper. Margin - Earnings Date - Volume 1,110,034 Change 14.29%
About AMARANTUS BIOSCIENCE HLDGS INC

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

AMBS Chatroom

User Image freegriff Posted - 03/30/24

$AMBS Magna dependents have agreed to SEC settlement language and the settlement is under final review by SEC for approval and Judges signature. Next update April 30. Hope to see some text soon and find out to what extent this judgement will benefit Amarantus.

User Image ZdP2 Posted - 03/20/24

$AMBS One of the most embarrasing US stocks ever. Keep on tweeting Gerald ! 🤣

User Image Kly49 Posted - 1 month ago

$AMBS what ever happened with Magna v SEC?

User Image dashtone Posted - 02/28/24

$AMBS I agree but he is not a scumbag to himself, he is robbing anyone that puts his money into this scam - he lives well wealthy and peaceful- a true scumbag

User Image dashtone Posted - 02/28/24

$AMBS it’s been delisted but it is left open to pinks this way they don’t have to payback anyone - true scumbags

User Image dashtone Posted - 02/28/24

$AMBS to those that comment in selling the company- the company was sold in 2020 to Todos, an Israeli company. They robbed all shareholders and left the building empty. No one persecutes these thieves and there is no law to hold them accountable- but who knows, maybe one day someone might meet the SCUMBAG CEO in a restaurant and bash his fucking head in the toilet

User Image rnalem Posted - 02/27/24

$AMBS is this delisted?

User Image Bulldog_Retired Posted - 2 months ago

@Captain_Jerk @HershJ Dr Arad had two patents approved since the Dec 2023 insolvency PR, both assigned to NCL Pharma Ltd https://patents.justia.com/inventor/dorit-arad Rapid detection test for SARS-CoV-2 Patent number: 11879893 Type: Grant Filed: August 9, 2022 Date of Patent: January 23, 2024 Assignee: NLC Pharma Ltd Inventor: Dorit Arad Compounds for treating corona virus infection Patent number: 11857517 Type: Grant Filed: August 14, 2022 Date of Patent: January 2, 2024 Assignee: NLC Pharma Ltd Inventor: Dorit Arad $AMBS $TOMDF

User Image Mandi63 Posted - 2 months ago

$AMBS If you can not do anything for shareholders..Sale this company! .25-$1.00 to any willing to develop MANF…..ITS TIME

User Image MoneyBarge Posted - 2 months ago

$AMBS Per stocktwits fundamentals, y car is worth more than the market capitalization of this company. Gerald, you should be ashamed of yourself. I bet I could rent my car out for more revenue than could be said for your company.

User Image Figgies Posted - 01/29/24

$AMBS looks like JP found a broker to sell shares..lol

User Image EarningsInsider Posted - 01/25/24

Amarantus BioScience Sees Short Interest Decrease from 89,000 shares to 31,200 shares. $AMBS https://www.marketbeat.com/stocks/OTCMKTS/AMBS

User Image freegriff Posted - 01/25/24

$AMBS another new publication from the Fins In conclusion, MANF protein expression is induced in activated microglia/macrophage cells in infarcted human and rodent brains, and this could implicate MANF’s involvement in the regulation of post-stroke inflammation in patients and experimental animals. Moreover, systemic delivery of recombinant MANF shows promising immunomodulatory effects and therapeutic potential in experimental ischemic stroke. https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-023-01701-y

User Image freegriff Posted - 01/22/24

$AMBS lol great day but up down or all around forget the trading until further notice. The fundamentals are as strong or stronger than ever.

User Image Figgies Posted - 01/22/24

$AMBS whoa..

User Image Skeetz99 Posted - 01/19/24

$AMBS I spoke to Schwab (my broker); it’s my understanding that the company may be behind on SEC filings/Financials. So, the trading is being restricted until more transparency is given by the company.

User Image MooseChuck Posted - 01/18/24

$AMBS What's going on today? 52 week low. Great.

User Image Vizzini Posted - 3 months ago

@Skeetz99 Yes, I tried. I use both Etrade and Fidelity brokerages. I could in the past up until last Friday, 1/12, but now both denied my orders, and I received the same message: "Opening transactions in Pink No Information, Grey Market, and Expert Market securities are not permitted due to the inherent risk associated with these products." it showed it has a volume of 1 today. How do you even buy 1 $AMBS share???

User Image Vizzini Posted - 3 months ago

$AMBS What's going on? No bids accepted or asked and no news??? Share same TOMDF fate !?!

User Image freegriff Posted - 3 months ago

@MooseChuck the timing is favorable for a publication on MANF in the new human-mouse models to be published before then. They figured out the new model last spring and have been testing since. $AMBS

User Image freegriff Posted - 3 months ago

$AMBS MANF is about to get its national stage Feb 29th 2:20pm Eastern. Dr. Urano has been invited to speak about gene and regenerative therapies for Wolfram syndrome at the Rare Disease Day Event 2024 at the National Institutes of Health. https://ncats.nih.gov/news-events/events/rdd 2:20 p.m. Rare Story #6: Wolfram Syndrome: Diagnosis, Clinical Protocols, and Advances in Gene Editing, Regenerative, and Molecular Targeted Therapies Fumihiko Urano, M.D., Ph.D., FACMG, Samuel E. Schechter Professor of Medicine, Director of Wolfram Syndrome and Related Disorders Clinic, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine in St. Louis

User Image yarekyarek Posted - 3 months ago

$AMBS please check on people involved in. Be safe

User Image Figgies Posted - 3 months ago

$AMBS

User Image freegriff Posted - 3 months ago

$AMBS Another new MANF study: Aging Neurotrophic factor MANF regulates autophagy and lysosome function to promote proteostasis in C. elegans From McMaster University in Canada ... We generated multiple transgenic strains overexpressing MANF-1 and found that animals had extended lifespan, reduced protein aggregation, and improved neuronal health. Using a fluorescently tagged MANF-1, we observed different tissue localization of MANF-1 depending on the ER retention signal. Further subcellular analysis showed that MANF-1 localizes within cells to the lysosomes. These findings were consistent with our transcriptomic studies and, together with analysis of autophagy regulators, demonstrate that MANF-1 regulates protein homeostasis through increased autophagy and lysosomal activity. Collectively, our findings establish MANF as a critical regulator of the stress response, proteostasis, and aging. https://www.biorxiv.org/content/10.1101/2023.07.31.551399v2

User Image freegriff Posted - 3 months ago

$AMBS 2024: the year MANF takes a leap forward towards clinical trials. Big Urano Lab update. Just a matter of time before Opris Bio, WashU and Amarantus team up. https://wolframsyndrome.wustl.edu/2631-2/

User Image JPStox Posted - 3 months ago

$AMBS what is book value here? Even with the pseudo bankruptcy filing this could be interesting.

User Image freegriff Posted - 12/30/23

$AMBS 2x New MANF publications 2/2 2. Deletion of mesencephalic astrocyte-derived neurotrophic factor delays and damages the development of white pulp in spleen from Anhui Provincial Children’s Hospital, in Immunobiology Volume 229, Issue 1, January 2024, 152778 "we found that MANF deficiency inhibited white pulp development in MANF knockout mice, thus indicating that MANF played an important role in the white pulp development of rodent spleen tissues." https://www.sciencedirect.com/science/article/pii/S0171298523045801

User Image freegriff Posted - 12/30/23

$AMBS 2x New MANF publications 1/2 1. Mesencephalic astrocyte-derived neurotrophic factor (MANF) alleviates cerebral ischemia/reperfusion injury in mice by regulating microglia polarization via A20/NF-κB pathway from China Pharmaceutical University, "The results showed that MANF decreased brain infarct volume, neurological scores, and brain water content. In addition, MANF promoted the polarization of microglia to an anti-inflammatory phenotype both in vivo and in vitro, which are related to A20/NF-κB pathway. In summary, MANF may offer novel therapeutic approaches for ischemic stroke in the process of microglia polarization." https://www.sciencedirect.com/science/article/abs/pii/S156757692301723X

User Image MoneyBarge Posted - 12/27/23

$AMBS I thought I would check in after several years. Just out of morbid curiosity. Right away I notice two things. 1st, stock is down 25% today which means someone bought a few shares only to have them immediately diluted 5 fold. So that scam is still in place. 2nd, that POS Gerald ex POS Stanford, should have been, a fourth string quarterback is still in slow motion running company into the ground. Please Gerald shoot yourself in the head like a real failed businessman would have done years ago.

User Image Bulldog_Retired Posted - 12/23/23

$TOMDF $AMBS so they owe about $ 80K to founder and about $ 300K to NLC, but their 100%-owned subsidiary Corona Diagnostics is owed over $5 million, so it’s bad management, but let’s set aside the GC bashing for a moment. Honest opinions from anyone knowledgeable in insolvency-drive reorganization, will this actually help focus Todos on what’s important and stop the chasing of every good (or bad) idea? in Israel is it likely the Trustee would support the reorganization in lieu of liquidation? https://investor.todosmedical.com/news-events/press-releases/detail/254/todos-medical-announces-insolvency-proceedings-in-israel